Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

First Patient Dosed in TNG456 Ph 1/2 Trial in Patients With MTAP-deleted GBM and Other Solid Tumors

May 27, 2025

Monotherapy and combination arms of BBI-355 in POTENTIATE trial to be discontinued; BBI-355 – BBI-825 combination to be investigated

May 27, 2025

IDeate-Esophageal01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

May 21, 2025

Clinical development of belrestotug to be discontinued

May 21, 2025

ADCT-602 trial to be discontinued

May 21, 2025

First Patient dosed in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumors

May 21, 2025

Successful End of Ph 2 Meeting with US FDA on Ph 3 Registrational Study Design for PT-112 in Patients with Metastatic CRPC Announced

May 21, 2025

GTB-3650 Ph 1 Trial Advanced to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 21, 2025

Ph 2 Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection initiated in metastatic CRPC

May 13, 2025

First Patient Dosed in STARt-002 Trial of Invikafusp Alfa in Combination with Trodelvy® in Metastatic Breast Cancer

May 13, 2025

Ph 1b Expansion Studies with JANX007 Initiated in Patients with Prostate Cancer

May 13, 2025

Ph 2 Trial of OX-4224 initiated in NSCLC

May 13, 2025

First patient dosed in the randomized Ph 1/2 study of roginolisib in combination with dostarlimab with or without docetaxel, in advanced NSCLC patients

May 13, 2025

Next phase of clinical development for cemsidomide to be enabled with new studies expected to initiate in early 2026

May 13, 2025

National SURVIVE study to proceed in GBM patients following interim analysis

May 13, 2025

Plans for Ph 3 1L vepdegestrant combo trial with atirmociclib and Ph 3 2L combination trial with a CDK4/6 inhibitor shelved

May 6, 2025

CAPItello-280 Ph 3 trial of Truqap (capivasertib) + docetaxel and ADT in patients with metastatic CRPC to be discontinued

May 6, 2025

First patient enrolled in Ph 1 trial of AKIR001 in solid tumors

May 6, 2025

Ph 1 study targeting GPC3 with 225Ac-GPC3 (BAY 3547926) in patients with advanced HCC initiated

May 6, 2025

Second Interim Analysis of OBI-822 Ph 3 Trial Completed and Trial Termination announced

April 30, 2025

Strategic Pipeline Prioritization Announced with Focus on CB-010 and CB-011 Oncology Programs

April 30, 2025

First Patient Dosed in Ph 2 Trial of MB-105 in T-Cell Lymphoma patients

April 30, 2025

Sarah Cannon Research Institute at Colorado Blood Cancer Institute Announced as Key Clinical Trial Site for Ph 1 Trial of CER-1236 in AML

April 30, 2025

First patient dosed in the GUARDIAN-101 Ph 1 trial of CLSP-1025

April 30, 2025

First patient dosed in Ph 1/2 Trial of AP402 in HER2+ Cancer Patients

April 30, 2025
Page1 Page2 Page3 … Page23

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.